pdufa.bio

Bitopertin

Page updated ·next FDA decision on the calendar ·Data as of Nov 12, 2026 2:24 AM ET

The FDA issued a Complete Response Letter for Bitopertin on Feb 15, 2026. 3 FDA decisions on record below. Every date links its source.

IRON catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

We track 3 catalyst events for this program: 0 upcoming and 3 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

FDA decision · Jan 21, 2025 ✓ ApprovedIRONFDA decision · Feb 13, 2026 CRLIRONFDA decision · Feb 15, 2026 CRLIRON

Specialist biotech funds holding IRON, 13F for the quarter ended June 30, 2026

FundSharesValue at quarter endFiling
RA Capital Management2,450,221$179.2 millionfiled August 14, 2026
BVF Inc.1,153,612$84.4 millionfiled August 14, 2026
OrbiMed Advisors357,535$26.2 millionfiled August 14, 2026
Baker Bros. Advisors349,657$25.6 millionfiled August 14, 2026
RTW Investments30,000$2.2 millionfiled August 14, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is Bitopertin's next FDA decision or readout?

No upcoming catalyst is on our calendar for Bitopertin; 3 FDA decisions are on record below.

What happened at Bitopertin's most recent FDA decision?

On Feb 15, 2026 the FDA issued a Complete Response Letter. The decision page carries the source document and the measured share-price reaction.

Has Bitopertin been approved by the FDA?

Yes. The FDA approved an application for Bitopertin on Jan 21, 2025; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.